Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brad Dajani

Neurology Coral Springs, FL Medical Doctor

NPI 1659494854 CMS profile 211199

1725 N University Dr, Suite425, Coral Springs, FL 33071

Open in the dashboard

General payments

$72,570

2,661 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brad Dajani of Coral Springs, FL is reported in the CMS Open Payments database as having received $72,570 across 2,661 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,466 333
2024 General $10,207 356
2023 General $9,003 343
2022 General $14,766 383
2021 General $10,155 446
2020 General $4,889 362
2019 General $10,085 438

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brad Dajani
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Brad Dajani were reported at $13,466. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Brad Dajani Neurology median Middle half National median
2019 $10,085 $474 $118–$2,177 $163
2020 $4,889 $367 $82–$2,309 $114
2021 $10,155 $438 $104–$2,547 $132
2022 $14,766 $442 $103–$2,388 $149
2023 $9,003 $464 $119–$2,312 $160
2024 $10,207 $468 $119–$2,323 $164
2025 $13,466 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Argenx US, Inc. $12,661 72 payments
  2. UCB, Inc. $5,753 189 payments
  3. AbbVie, Inc. $3,791 170 payments
  4. ACADIA Pharmaceuticals Inc $3,243 136 payments
  5. Teva Pharmaceuticals USA, Inc. $3,203 123 payments
  6. Alexion Pharmaceuticals, Inc. $3,048 101 payments
  7. Novartis Pharmaceuticals Corporation $2,839 127 payments
  8. Biogen, Inc. $2,544 128 payments
  9. Biohaven Pharmaceuticals, Inc. $2,453 77 payments
  10. EMD Serono, Inc. $2,365 62 payments
  11. Other $30,670 1,476 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $59,332 2,618 payments
  2. Consulting Fee $9,760 3 payments
  3. Travel and Lodging $2,744 13 payments
  4. Education $481 17 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $253 10 payments
Products named General payments · program years 2019–2025
  1. VYVGART Hytrulo $6,110 50 payments
  2. NURTEC ODT $2,934 112 payments
  3. UBRELVY $2,307 98 payments
  4. NUPLAZID $2,250 87 payments
  5. AIMOVIG $1,767 70 payments
  6. NUEDEXTA $1,749 142 payments
  7. INGREZZA $1,634 89 payments
  8. Zilbrysq $1,410 1 payment
  9. ULTOMIRIS $1,340 44 payments
  10. TYSABRI $1,309 69 payments
  11. Other $45,254 2,059 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

3,370

Median for Neurology: 833

Drug cost

$1,415,426

Median for Neurology: $202,670

Branded share of claims

29.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ultomiris Ravulizumab-Cwvz Brand 14 $529,324
Nuplazid Pimavanserin Tartrate Brand 32 $156,579
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 18 $149,585
Ingrezza Valbenazine Tosylate Brand 12 $95,202
Nuedexta Dextromethorphan Hbr/Quinidine Brand 31 $53,326
Botox Onabotulinumtoxina Brand 41 $52,429
Rexulti Brexpiprazole Brand 31 $51,081
Nurtec Odt Rimegepant Sulfate Brand 39 $45,660
Xeomin Incobotulinumtoxina Brand 30 $45,285
Fycompa Perampanel Brand 31 $41,410

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$207,547

Of which drugs: $52,247

Medicare patients

457

Average age 75

Services billed

12,216

250 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Diabetes 49%
Ischemic heart disease 48%
Depression 37%
Chronic kidney disease 33%
Alzheimer's or dementia 31%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 23 9,800 $47,967

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilbrysq
$1,720 — —
VALTOCO
$487 11 —
Fintepla
$440 — —
ULTOMIRIS
$427 14 —
VYVGART Hytrulo
$424 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

2,661 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record